Search
Monopar Therapeutics Inc
MNPRAdd to Watchlist
97.790USD
+2.760+2.90%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
655.10MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.90%
5 Days
+11.53%
1 Month
+64.05%
6 Months
+48.14%
Year to Date
+49.75%
1 Year
+169.77%
Key Figures
95.440Open
100.000High
188.27KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.81%Turnover Ratio
95.030Prev. Close
93.590Low
8.81MTurnover
LossP/E Static
4.84P/B
0.00%Div Yield TTM
-15.52%ROA
105.00052wk High
1.75Volume Ratio
-15.59MNet Profit
6.70MShares
-1.9313EPS TTM
1.53Beta
-15.86%ROE
28.40052wk Low
6.75%Amplitude
--Gross Margin
655.10MMarket Cap
11.93Reward/Risk
4.98%Risk Rate
TradingKey Stock Score of Monopar Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Monopar Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 66 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 113.62.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Monopar Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
No data
Monopar Therapeutics Inc Highlights
StrengthsRisks
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -50.63, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 5.90M shares, increasing 15.51% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 254.69 shares of this stock.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
113.615
Target Price
+19.56%
Upside Space
Monopar Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Monopar Therapeutics Inc Info
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Ticker SymbolMNPR
CompanyMonopar Therapeutics Inc
CEORobinson (Chandler D)
Websitehttps://www.monopartx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Monopar Therapeutics Inc (MNPR)?
The current price of Monopar Therapeutics Inc (MNPR) is 97.79.
What is the symbol of Monopar Therapeutics Inc?
The ticker symbol of Monopar Therapeutics Inc is MNPR.
What is the 52-week high of Monopar Therapeutics Inc?
The 52-week high of Monopar Therapeutics Inc is 105.00.
What is the 52-week low of Monopar Therapeutics Inc?
The 52-week low of Monopar Therapeutics Inc is 28.40.
What is the market capitalization of Monopar Therapeutics Inc?
The market capitalization of Monopar Therapeutics Inc is 655.10M.
Is Monopar Therapeutics Inc (MNPR) currently rated as Buy, Hold, or Sell?
According to analysts, Monopar Therapeutics Inc (MNPR) has an overall rating of Buy, with a price target of 113.62.
What is the Earnings Per Share (EPS TTM) of Monopar Therapeutics Inc (MNPR)?
The Earnings Per Share (EPS TTM) of Monopar Therapeutics Inc (MNPR) is -1.85.